Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2020Clinical pharmacology and therapyOpen Access

Tofacitinib in rheumatoid arthritis: what is new?

View Full Paper
Ask AI
Bookmark
Share

Key result

Tofacitinib matches biologic DMARDs in treating rheumatoid arthritis as monotherapy or combined with methotrexate.

Authors

ЕНЕ. Л. Насонов

Discussion

Loading...

Member takes

Overview

Level 5 evidence leaves open any clinical relevance; randomized trials required before cardiovascular adoption.

PICO

P
Population
A comprehensive review of the efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients with rheumatoid arthritis across multiple phase III clinical trials and real-world registries.
I
Intervention / Comparator
Tofacitinib vs Placebo, Methotrexate, or Biologic DMARDs (5 mg twice daily or 11 mg once daily)

Limitations

  • Increased risk of certain infections, particularly herpes zoster
  • Potential risk of venous thromboembolism, especially in patients with existing risk factors

Cite This Study

Е. Л. Насонов (2020) conducted a review in Rheumatoid arthritis. Tofacitinib vs. Placebo, Methotrexate, or Biologic DMARDs was evaluated. Tofacitinib demonstrates efficacy comparable to biologic disease-modifying antirheumatic drugs in treating rheumatoid arthritis, both as monotherapy and in combination with methotrexate.

synapsesocial.com/papers/6aa9409c6dc8754dbe62eb03https://doi.org/10.32756/0869-5490-2020-1-5-12
View Full Paper
Ask AI
Bookmark
Share